Institutional members access full text with Ovid®

Share this article on:

Helping Patients Make the Best Decision Regarding Duration of Temozolomide Chemotherapy Treatment

Groves, Morris D. Jr MD, JD; Plummer, Ava B. MPH, JD

CONTINUUM: Lifelong Learning in Neurology: April 2012 - Volume 18 - Issue 2, Neuro-oncology - p 421–425
doi: 10.1212/01.CON.0000413668.65668.4a
Practice Issues

Outcomes for patients with glioblastoma have improved with the addition of temozolomide (TMZ) chemotherapy to radiation therapy followed by adjuvant TMZ for up to 1 year. Patients often wish to continue chemotherapy after the standard 1-year course. Whether to continue or to stop TMZ is a complex and stressful decision for the patient and family, and the decision should be based on a discussion of the known risks and benefits of each choice.

Address correspondence to Dr Morris D. Groves, 901 West 38th Street, Suite 200, Austin, TX 78705,

Relationship Disclosure: Dr Groves has served as a speaker for Merck and Co., Inc. and has served on the advisory board for Genentech, Inc., and Sanofi-Aventis. Dr Groves received research support for brain tumor research from Angiochem, Celldex, Inc., Enzon Pharmaceuticals, Inc., Genentech, Inc., Merck and Co., Inc., and Reata Pharmaceuticals, Inc. Ms Plummer reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Groves and Ms Plummer report no disclosure.

© 2012 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website